COMP <GO>
TARA vs MOLN // ALTMAN Z-SCORE & DEBT/EQUITY
Protara Therapeutics Inc. (NASDAQ) VS. Molecular Partners AG (NASDAQ) • 15-METRIC TALLY: TARA 1
— MOLN 1
■ METRIC PARITY
LAST: $2.41 (-2.82%) • MKT CAP: $146.6M
balance-sheet
—
LAST: $3.48 (-2.79%) • MKT CAP: $134.3M
balance-sheet
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TARA VS. MOLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TARA | MOLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.70% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.3 | 41.5 | -3.20 | MOLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $146.6M | $134.3M | $12.3M | TARA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TARA REV | MOLN REV | TARA GROSS % | MOLN GROSS % | TARA FCF | MOLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $180.7M | — | — | — | -$56.5M | — |
| FY 2024 | $137.6M | — | — | — | -$35.9M | — |
| FY 2023 | $122.1M | — | — | — | -$37.6M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TARA // BETA —
MOLN // BETA —